This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción MGNK
Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and human immunodeficiency virus (HIV).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Competidores de Mologen AG
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €0.005 |
| 52 Week High | €0.035 |
| 52 Week Low | €0.003 |
| Beta | 0 |
| 1 Month Change | -28.57% |
| 3 Month Change | -28.57% |
| 1 Year Change | -77.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.67% |
Noticias y actualizaciones recientes
No hay actualizaciones
Recent updates
No hay actualizaciones
Rentabilidad de los accionistas
| MGNK | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 25.0% | -4.9% | -1.5% |
| 1Y | -77.7% | -19.9% | 0.9% |
Rentabilidad vs. Industria: MGNK underperformed the German Biotechs industry which returned -4% over the past year.
Rentabilidad vs. Mercado: MGNK underperformed the German Market which returned -24.2% over the past year.
Volatilidad de los precios
| MGNK volatility | |
|---|---|
| MGNK Average Weekly Movement | 83.4% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: MGNK's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: MGNK's weekly volatility has increased from 59% to 83% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1998 | n/a | n/a | www.mologen.com |
Resumen de fundamentos de Mologen AG
| Estadísticas fundamentales de MGNK | |
|---|---|
| Capitalización bursátil | €62.18k |
| Beneficios(TTM) | -€13.67m |
| Ingresos (TTM) | €386.00k |
0.0x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está MGNK sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MGNK | |
|---|---|
| Ingresos | €386.00k |
| Coste de los ingresos | €4.80m |
| Beneficio bruto | -€4.41m |
| Otros gastos | €9.25m |
| Beneficios | -€13.67m |
Últimos beneficios comunicados
Sep 30, 2019
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0.0% |
¿Cómo se ha desempeñado MGNK a largo plazo?
Ver rendimiento histórico y comparativa